KTD-092
KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases[1].
Product Specifications
UNSPSC
12352005
Target
DYRK
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Smiles
CCN1C=NN=C1C2=NC(NC(C3=CC(OC)=C(C=C3OC)OC)=O)=CC=C2
Molecular Formula
C19H21N5O4
Molecular Weight
383.40
References & Citations
[1]Sujeong Hong, et al. Discovery of 2- (1,2,4-triazol-3-yl) pyridine KTD-092 as a novel DYRK1A. Wiley Online Library inhibitor. 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DYRK1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681429-100 1x 100 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942103-500 1x 500 µL
Cytokeratin 15 (Esophageal Squamous Cell Carcinoma Marker) (KRT15/2103R), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details